These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 1174022

  • 1. Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA).
    Nichols DE, Ilhan M, Long JP.
    Arch Int Pharmacodyn Ther; 1975 Mar; 214(1):133-40. PubMed ID: 1174022
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interactions of catecholaminergic receptor blockers with lethal doses of amphetamine or substituted amphetamines in mice.
    Davis WM, Hatoum HT, Waters IW.
    Res Commun Chem Pathol Pharmacol; 1978 Jul; 21(1):27-36. PubMed ID: 687391
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines.
    Menon MK, Tseng LF, Loh HH.
    J Pharmacol Exp Ther; 1976 May; 197(2):272-9. PubMed ID: 946817
    [Abstract] [Full Text] [Related]

  • 7. Cardiovascular effects of novel amphetamine analogs in anesthetized rats.
    Thompson E, Wood L.
    Res Commun Chem Pathol Pharmacol; 1978 Sep; 21(3):447-56. PubMed ID: 705023
    [Abstract] [Full Text] [Related]

  • 8. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation.
    Jaehne EJ, Salem A, Irvine RJ.
    Pharmacol Biochem Behav; 2005 Jul; 81(3):485-96. PubMed ID: 15904952
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Letter: Properties of PME.
    Bell JI, Yee R, Cook DA, Paton DM.
    Can Med Assoc J; 1974 Sep 07; 111(5):388. PubMed ID: 4414360
    [No Abstract] [Full Text] [Related]

  • 15. The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine.
    Kaminskas LM, Irvine RJ, Callaghan PD, White JM, Kirkbride P.
    Psychopharmacology (Berl); 2002 Mar 07; 160(2):155-60. PubMed ID: 11875633
    [Abstract] [Full Text] [Related]

  • 16. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse.
    Davis WM, Hatoum HT, Waters IW.
    Alcohol Drug Res; 1987 Mar 07; 7(3):123-34. PubMed ID: 2881551
    [Abstract] [Full Text] [Related]

  • 17. Effect of amphetamine, 3,4-methylenedioxyamphetamine, p-methoxyamphetamine and related amphetamines on uptake of metaraminol and efflux of noradrenaline in adrenergic nerves of rabbit atria.
    Paton DM.
    J Pharm Pharmacol; 1975 May 07; 27(5):361-2. PubMed ID: 239139
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
    Hewton R, Salem A, Irvine RJ.
    Clin Exp Pharmacol Physiol; 2007 Oct 07; 34(10):1051-7. PubMed ID: 17714093
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.